ArticleAnnals of internal medicine2010
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.
Article in Annals of internal medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 3 syntheses or guidelines pooled it, 455 citations in OpenAlex.
- FGF-23 as a Biomarker for Carotid Plaque Vulnerability: A Systematic Review.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2018Pooled it
- Vitamin D in the prevention of left ventricular remodelling after an acute myocardial infarction: a randomized clinical trial.Scientific reports · 2026Trial
- Trial
- Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy.Medicine · 2016Trial
- Trial
- Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Trial
- Trial
- Trial
- Fibroblast growth factor 23 and incident CKD in type 2 diabetes.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized Trial.PloS one · 2015Trial
- Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.Critical care (London, England) · 2014Trial
- Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.Journal of the American College of Cardiology · 2014Trial
- Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease.PloS one · 2013Trial
- Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism.International urology and nephrology · 2012Trial
- Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.Clinical journal of the American Society of Nephrology : CJASN · 2012Trial
- Racial differences in markers of mineral metabolism in advanced chronic kidney disease.Clinical journal of the American Society of Nephrology : CJASN · 2012Trial
- Phosphorus is associated with coronary artery disease in patients with preserved renal function.PloS one · 2012Trial
- Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women.European journal of endocrinology · 2011Trial
158 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 1 institution in 3 countries.
Funding
Abstract
backgroundFibroblast growth factor 23 (FGF23), uncarboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibitors of vascular calcification. Whether circulating levels of each are associated with cardiovascular disease (CVD) events or mortality in populations without end-stage renal disease is unknown.
objectiveTo evaluate the associations of FGF23, ucMGP, and fetuin-A with mortality and CVD events.
designObservational study.
setting12 outpatient clinics in the San Francisco Bay area. PATIENTS: 833 outpatients with stable coronary artery disease (CAD), recruited from 11 September 2000 to 20 December 2002. MEASUREMENTS: Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline. Participants were followed until 1 December 2008 for mortality and CVD events.
resultsDuring a median follow-up of 6.0 years, 220 participants died and 182 had CVD events. Compared with participants with FGF-23 levels in the lowest tertile, those in the highest tertile had 2-fold greater risk for mortality (hazard ratio [HR], 2.15 [95% CI, 1.43 to 3.24]) and CVD events (HR, 1.83 [CI, 1.15 to 2.91]) after adjustment for traditional CVD risk factors, C-reactive protein levels, and kidney function. The highest ucMGP tertile was associated with lower mortality risk (HR, 0.48 [CI, 0.31 to 0.75]) and showed a nonsignificant trend toward lower CVD event risk by tertile analysis (HR, 0.65 [CI, 0.40 to 1.05])-an association that was significant when modeled continuously (P = 0.029). No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or CVD events (HR, 0.99 [CI, 0.64 to 1.55]) was observed. LIMITATION: Participants had prevalent CAD.
conclusionIn outpatients with stable CAD, higher FGF23 and lower ucMGP levels are independently associated with mortality and CVD events. PRIMARY FUNDING SOURCE: American Heart Association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.